Readystate Asset Management LP Invests $4.40 Million in MiniMed Group Inc $MMED

Key Points

• Readystate Asset Management acquired 294,284 MiniMed Group shares worth approximately $4.4 million, representing about 0.10% of the company. Several other institutions also initiated or increased positions during the second quarter.
• Analyst sentiment is broadly positive: 13 analysts rate MMED a Buy, with a consensus rating of “Moderate Buy” and an average price target of $23.77. Recent firms including BTIG, Citigroup, Bank of America and Mizuho raised their targets.
• MiniMed’s outlook is supported by new product launches, recurring revenue, regulatory progress and a strong start to fiscal 2027. The stock opened at $23.28, near its 12-month high of $24.43, with a market capitalization of roughly $6.55 billion.

Readystate Asset Management LP bought a new stake in shares of MiniMed Group Inc (NASDAQ:MMED - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 294,284 shares of the company's stock, valued at approximately $4,400,000. Readystate Asset Management LP owned approximately 0.10% of MiniMed Group at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Washington Growth Strategies LLC bought a new position in shares of MiniMed Group during the 2nd quarter worth approximately $397,000. Punch & Associates Investment Management Inc. bought a new position in MiniMed Group during the second quarter worth $292,000. Bank of America Corp DE increased its stake in MiniMed Group by 377.0% in the second quarter. Bank of America Corp DE now owns 238,819 shares of the company's stock valued at $3,570,000 after purchasing an additional 188,756 shares in the last quarter. Freestone Grove Partners LP bought a new position in shares of MiniMed Group during the 2nd quarter worth about $1,745,000. Finally, J. Goldman & Co LP acquired a new stake in shares of MiniMed Group in the 2nd quarter valued at about $12,412,000.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

Analyst Upgrades and Downgrades

MMED has been the topic of several recent research reports. BTIG Research increased their price target on MiniMed Group from $25.00 to $28.00 and gave the stock a "buy" rating in a report on Tuesday, September 1st. Benchmark reaffirmed a "buy" rating on shares of MiniMed Group in a research report on Thursday, June 4th. Citigroup increased their target price on MiniMed Group from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd. Bank of America boosted their price target on shares of MiniMed Group from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Finally, Mizuho upped their price objective on shares of MiniMed Group from $21.00 to $26.00 and gave the stock an "outperform" rating in a report on Wednesday, September 2nd. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.77.

MiniMed Group Stock Down 0.0%

MMED stock opened at $23.28 on Monday. The company has a market capitalization of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group Inc has a twelve month low of $10.65 and a twelve month high of $24.43. The firm has a 50 day moving average of $18.21.

MiniMed Group Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

Want to see what other hedge funds are holding MMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiniMed Group Inc (NASDAQ:MMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source